The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Targeting RAS signalling pathways in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Social controls on cell survival and cell death
Raff, M. C. (1992) · Nature · doi:10.1038/356397a0 · Cited by 2,604
Takai, Y., Sasaki, T., & Matozaki, T. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.153 · Cited by 2,475
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Self-citationAll ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
Daub, H., Ulrich Weiss, F., Wallasch, C., & Ullrich, A. (1996) · Nature · doi:10.1038/379557a0 · Cited by 1,476
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
FUNCTION AND REGULATION OF RAS
Lowy, D. R., & Willumsen, B. M. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.004223 · Cited by 1,186
Increasing complexity of Ras signaling
Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., & Der, C. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202174 · Cited by 1,079
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,059
Khwaja, A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2783 · Cited by 1,039
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Stimulation of p21ras upon T-cell activation
Downward, J., Graves, J. D., Warne, P. H., Rayter, S., & Cantrell, D. A. (1990) · Nature · doi:10.1038/346719a0 · Cited by 860
Self-citationMolecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Understanding Ras: ‘it ain’t over ’til it’s over’
Shields, J. M., Pruitt, K., McFall, A., Shaub, A., & Der, C. J. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01740-2 · Cited by 780
Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202367 · Cited by 691
RasGRP, a Ras Guanyl Nucleotide- Releasing Protein with Calcium- and Diacylglycerol-Binding Motifs
Ebinu, J. O., Bottorff, D. A., Chan, E. Y. W., Stang, S. L., Dunn, R. J., & Stone, J. C. (1998) · Science · doi:10.1126/science.280.5366.1082 · Cited by 689
PTEN: Life as a Tumor Suppressor
Simpson, L., & Parsons, R. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5130 · Cited by 679
Hsp90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02316-x · Cited by 677
Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.
Marais, R., Light, Y., Paterson, H. F., & Marshall, C. J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07316.x · Cited by 612
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ
Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 602
Ras signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594 · cited 1×
“Several other non-receptor proteins can also become tyrosine phosphorylated and act as anchors for GRB2 interaction, and there are several other GEFs for RAS that are controlled quite differentl”
BackgroundThe rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Hidalgo, M., & Rowinsky, E. K. (2000) · Oncogene · doi:10.1038/sj.onc.1204091 · Cited by 582
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
Zucker, S., Cao, J., & Chen, W.-T. (2000) · Oncogene · doi:10.1038/sj.onc.1204097 · Cited by 550
K-ras is an essential gene in the mouse with partial functional overlap with N-ras
Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 545
Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., Desolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., et al. (1995) · Nature Medicine · doi:10.1038/nm0895-792 · Cited by 540
Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3234 · Cited by 474
Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., & Fabbro, D. (1996) · Nature Medicine · doi:10.1038/nm0696-668 · Cited by 447
Herbst, R. S., & Shin, D. M. (2002) · Cancer · doi:10.1002/cncr.10372 · Cited by 446
Discovery of a novel Raf kinase inhibitor.
Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080219 · Cited by 416
The Ras branch of small Gtpases: Ras family members don’t fall far from the tree
Reuther, G. W., & Der, C. J. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00071-x · Cited by 413
Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours
Malliri, A., van der Kammen, R. A., Clark, K., van der Valk, M., Michiels, F., & Collard, J. G. (2002) · Nature · doi:10.1038/nature00848 · Cited by 384
Integration of calcium and RAS signalling
Cullen, P. J., & Lockyer, P. J. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm808 · Cited by 378
Phospholipase Cepsilon: a novel Ras effector
Kelley, G. G. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.743 · Cited by 361
Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism
Lambert, J. M., Lambert, Q. T., Reuther, G. W., Malliri, A., Siderovski, D. P., Sondek, J., Collard, J. G., & Der, C. J. (2002) · Nature Cell Biology · doi:10.1038/ncb833 · Cited by 326
Signal transduction and the Ets family of transcription factors
Yordy, J. S., & Muise-Helmericks, R. C. (2000) · Oncogene · doi:10.1038/sj.onc.1204036 · Cited by 325
EGF mutant receptor vIII as a molecular target in cancer therapy.
Kuan, C. T., Wikstrand, C. J., & Bigner, D. D. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080083 · Cited by 323
Development of anticancer drugs targeting the MAP kinase pathway
Sebolt-Leopold, J. S. (2000) · Oncogene · doi:10.1038/sj.onc.1204083 · Cited by 320
Ras and Rho regulation of the cell cycle and oncogenesis
Pruitt, K., & Der, C. J. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00528-6 · Cited by 311
MEK kinase activity is not necessary for Raf-1 function
Huser, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1940 · Cited by 310
The EGF Receptor Provides an Essential Survival Signal for SOS-Dependent Skin Tumor Development
Sibilia, M., Fleischmann, A., Behrens, A., Stingl, L., Carroll, J., Watt, F. M., Schlessinger, J., & Wagner, E. F. (2000) · Cell · doi:10.1016/s0092-8674(00)00026-x · Cited by 304
Sebti, S. M., & Hamilton, A. D. (2000) · Oncogene · doi:10.1038/sj.onc.1204146 · Cited by 279
Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
Cox, A. D., & Der, C. J. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00011-5 · Cited by 266
Membrane Association and Targeting of Prenylated Ras-like GTPases
Seabra, M. C. (1998) · Cellular Signalling · doi:10.1016/s0898-6568(97)00120-4 · Cited by 261
Analysis of the transcriptional program induced by Raf in epithelial cells
Schulze, A., Lehmann, K., Jefferies, H. B. J., McMahon, M., & Downward, J. (2001) · Genes & Development · doi:10.1101/gad.191101 · Cited by 259
Self-citationLobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H., Brucker, M. J., Buser, C. A., Davide, J. P., DeSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M., et al. (2001) · PubMed · Cited by 239
Actin' up: RhoB in cancer and apoptosis
Prendergast, G. C. (2001) · Nature Reviews Cancer · doi:10.1038/35101096 · Cited by 234
The role of EGF-related peptides in tumor growth
Normanno, N. (2001) · Frontiers in Bioscience · doi:10.2741/a635 · Cited by 216
GTPase activating proteins: critical regulators of intracellular signaling
Donovan, S., Shannon, K. M., & Bollag, G. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00041-5 · Cited by 215
Cortes, J., Albitar, M., Thomas, D., Giles, F., Kurzrock, R., Thibault, A., Rackoff, W., Koller, C., O'Brien, S., Garcia-Manero, G., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1973 · Cited by 206
The ErbB receptor family: a therapeutic target for cancer
de Bono, J. S., & Rowinsky, E. K. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02306-7 · Cited by 202
Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA
(1991) · Lung Cancer · doi:10.1016/0169-5002(91)90412-y · Cited by 188
Mechanism of 17-β-Estradiol-induced Erk1/2 Activation in Breast Cancer Cells
Keshamouni, V. G., Mattingly, R. R., & Reddy, K. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202351200 · Cited by 174
Guanosine triphosphatase stimulation of oncogenic Ras mutants
Ahmadian, M. R., Zor, T., Vogt, D., Kabsch, W., Selinger, Z., Wittinghofer, A., & Scheffzek, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.7065 · Cited by 144
Kato‐Stankiewicz, J., Hakimi, I., Zhi, G., Zhang, J., Serebriiskii, I. G., Guo, L., Edamatsu, H., Koide, H., Menon, S., Eckl, R. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222222699 · Cited by 143
Absence of the CAAX Endoprotease Rce1: Effects on Cell Growth and Transformation
Bergö, M. O., Ambroziak, P., Gregory, C., George, A. M., Otto, J. C., Kim, E. J.-H., Nagase, H., Casey, P. J., Balmain, A., & Young, S. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.171-181.2002 · Cited by 142
Farnesyltransferase inhibitors: promises and realities
Cox, A. D. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00181-9 · Cited by 141
Rational therapeutic intervention in cancer: kinases as drug targets
Sawyers, C. L. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00273-8 · Cited by 129
Wittinghofer, A. (1998) · PubMed · Cited by 117
Rose, W. C., Lee, F. Y., Fairchild, C. R., Lynch, M. J., Monticello, T. M., Kramer, R. A., & Manne, V. (2001) · PubMed · Cited by 108
de Ruiter, N. D., Burgering, B. M. T., & Bos, J. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.23.8225-8235.2001 · Cited by 100
Protein tyrosine kinase inhibitors: new treatment modalities?
Fabbro, D. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00179-0 · Cited by 86
Replication-selective viruses for cancer therapy
Biederer, C. H., Ries, S. J., Brandts, C., & McCormick, F. P. (2001) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0295-1 · Cited by 86
Coudert, B. P., Anthoney, A., Fiedler, W., Droz, J., Dieras, V. C., Borner, M., Smyth, J. F., Morant, R., de Vries, M. J., Roelvink, M., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00286-6 · Cited by 83
The emerging fields of suicide gene therapy and virotherapy
Kirn, D. H., Niculescu‐Duvaz, I., Halldén, G., & Springer, C. J. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02318-3 · Cited by 79
Epidermal growth factor receptor tyrosine kinase inhibitors
Wakeling, A. E. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00183-2 · Cited by 78
Potential roles of antisense technology in cancer chemotherapy
Crooke, S. T. (2000) · Oncogene · doi:10.1038/sj.onc.1204093 · Cited by 73
Inhibitors of Protein Farnesyltransferase as Novel Anticancer Agents
Ohkanda, J., Knowles, D. B., Blaskovich, M. A., Sebti, S. M., & Hamilton, A. D. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023394281 · Cited by 70
ZD1839: targeting the epidermal growth factor receptor in cancer therapy
Herbst, R. S. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.6.837 · Cited by 57
Felix Hoppe-Seyler Lecture 1998
(1998) · Biological Chemistry · doi:10.1515/bchm.1998.379.8-9.933 · Cited by 57
Concepts in Ras-directed therapy
Kloog, Y., Cox, A. D., & Sinensky, M. S. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.12.2121 · Cited by 52
Hunger, R. E., Brand, C. U., Streit, M., Eriksen, J. A., Gjertsen, M. K., Sæterdal, I., Braathen, L. R., & Gaudernack, G. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.010003161.x · Cited by 42
Xie, Y., Li, K., & Hung, M. (1995) · PubMed · Cited by 32
RNA aptamers that specifically bind to the Ras‐binding domain of Raf‐1
Kimoto, M., Sakamoto, K., Shirouzu, M., Hirao, I., & Yokoyama, S. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01572-5 · Cited by 21
Research works printed but not linked: 5
- Weiss, B., Bollag, G. & Shannon, K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am. J. Med. Genet. 89, 14–22 (1999). · doi:10.1002/(sici)1096-8628(19990326)89:1<14::aid-ajmg5>3.0.co;2-4
- Singh, S. B. & Lingham, R. B. Current progress on farnesyl protein transferase inhibitors. Curr. Opin. Drug. Discov. Devel. 5, 225–244 (2002).
- Chen, G., Oh, S., Monia, B. P. & Stacey, D. W. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J. Biol. Chem. 271, 28259–28265 (1996). · doi:10.1074/jbc.271.45.28259
- Reuveni, H. et al. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 41, 10304–10314 (2002). · doi:10.1021/bi0202530
- Rosen, L. S. Angiogenesis inhibition in solid tumors. Cancer J. 7 (Suppl. 3), S120–S128 (2001).
Cited by
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Metadata
- Authors
- Downward, J.
- Venue
- Nature Reviews Cancer
- Published
- 2003-01
- Volume
- 3
- Issue
- 1
- Pages
- 11-22
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2080719056
- Cited by
- 3,256
- References
- 83
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.